Rosa Lamarca
- Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyBy Paul W. Jones, Dave Singh, Eric D. Bateman, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Rosa Segarra, Cynthia Caracta and Esther Garcia GilPaul W. Jones*St George's, University of London, LondonDave Singh#University of Manchester, Medicines Evaluation Unit Ltd, Manchester, UKEric D. Bateman¶University of Cape Town, Cape Town, South Africa,Alvar Agusti+Thorax Institute, Hospital Clínic, University of Barcelona, and Fundación Investigación Sanitaria Illes Balears (FISIB), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), MallorcaRosa Lamarca§Almirall SA, Barcelona, SpainGonzalo de Miquel§Almirall SA, Barcelona, SpainRosa Segarra§Almirall SA, Barcelona, SpainCynthia CaractafForest Research Institute, Jersey City, NJ, USAEsther Garcia Gil§Almirall SA, Barcelona, Spain
- Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAINBy Alvar Agusti, Paul W. Jones, Eric Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilAlvar Agusti1Thorax Institute, Hospital Clínic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainPaul W. Jones2St George's, University of London, London, United KingdomEric Bateman3Department of Pulmonology, University of Cape Town, Cape Town, South AfricaDavid Singh4Medicines Evaluation Unit, University of South Manchester, Manchester, United KingdomRosa Lamarca5R&D Centre, Amirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Amirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Amirall, Barcelona, Spain
- The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary diseaseBy Eric D. Bateman, David Singh, Paul W. Jones, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilEric D. Bateman1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South AfricaDavid Singh2Medicines Evaluation Unit, University of Manchester, Manchester, United KingdomPaul W. Jones3St George's, University of London, London, United KingdomAlvar Agusti4Thorax Institute, Hospital Clinic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)By David Singh, Eric D. Bateman, Paul W. Jones, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilDavid Singh1Medicines Evaluation Unit, University of Manchester, Manchester, United KingdomEric D. Bateman2Division of Pulmonology, University of Cape Town, Cape Town, South AfricaPaul W. Jones3St George's, University of London, London, United KingdomAlvar Agusti4Thorax Institute, Hospital Clínic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAINBy Paul W. Jones, Alvar Agusti, Eric D. Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilPaul W. Jones1St George's, University of London, London, United KingdomAlvar Agusti2Thorax Institute, Hospital Clinic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainEric D. Bateman3Department of Pulmonology, University of Cape Town, Cape Town, South AfricaDavid Singh4Medicines Evaluations Unit, University of Manchester, Manchester, United KingdomRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trialsBy Paul Jones, Edward Kerwin, Eric Bateman, Rosa Lamarca, Cynthia Caracta and Esther Garcia GilPaul Jones1Division of Clinical Sciences, St. George's University, London, United KingdomEdward Kerwin2Clinical Research Institute, Medford, United StatesEric Bateman3Respiratory Medicine, University of Cape Town Lung Institute, Cape Town, South AfricaRosa Lamarca4Clinical Statistics, Almirall, S.A., Barcelona, SpainCynthia Caracta5Clinical Development, Forest Research Institute, Jersey City, United StatesEsther Garcia Gil6R&D Centre, Almirall, S.A., Barcelona, Spain
- Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAINBy Paul W. Jones, David Singh, Alvar Agusti, Eric D. Bateman, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilPaul W. Jones1St George's, University of London, United KingdomDavid Singh2Medicines Evaluation Unit Ltd, Manchester, United KingdomAlvar Agusti3Thorax Institute, Hospital Clínic, Barcelona, and CIBER Enfermedades Respiratorias and Fundació Caubet-Cimera, Barcelona, SpainEric D. Bateman4University of Cape Town, South AfricaRosa Lamarca5Almirall S.A, Barcelona, SpainGonzalo de Miquel5Almirall S.A, Barcelona, SpainCynthia Caracta6Forest Research Institute, NJ, United StatesEsther Garcia Gil5Almirall S.A, Barcelona, Spain
- Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN studyBy Paul W. Jones, Dave Singh, Eric D. Bateman, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Rosa Segarra, Cynthia Caracta and Esther Garcia GilArticle | Published in 2012 in European Respiratory JournalPaul W. JonesDave SinghEric D. BatemanAlvar AgustiRosa LamarcaGonzalo de MiquelRosa SegarraCynthia Caracta
- Characterisation and impact of reported and unreported exacerbations: results from ATTAINBy Paul W. Jones, Rosa Lamarca, Ferran Chuecos, Dave Singh, Alvar Agustí, Eric D. Bateman, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilArticle | Published in 2014 in European Respiratory JournalPaul W. Jones1Division of Clinical Science, St George’s, University of London, London, UKRosa Lamarca2R&D Centre, Almirall, Barcelona, SpainFerran Chuecos2R&D Centre, Almirall, Barcelona, SpainDave Singh3Medicines Evaluation Unit, University Hospital of South Manchester, Manchester, UKAlvar Agustí4Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain5FISIB, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Mallorca, SpainEric D. Bateman6Dept of Medicine, University of Cape Town, Cape Town, South AfricaGonzalo de Miquel2R&D Centre, Almirall, Barcelona, SpainCynthia Caracta7Forest Research Institute, Forest Laboratories Inc., Jersey City, NJ, USAEsther Garcia Gil2R&D Centre, Almirall, Barcelona, Spain
- Characterisation and impact of reported and unreported exacerbations: results from ATTAINBy Paul W. Jones, Rosa Lamarca, Ferran Chuecos, Dave Singh, Alvar Agustí, Eric D. Bateman, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilPaul W. Jones1Division of Clinical Science, St George’s, University of London, London, UKRosa Lamarca2R&D Centre, Almirall, Barcelona, SpainFerran Chuecos2R&D Centre, Almirall, Barcelona, SpainDave Singh3Medicines Evaluation Unit, University Hospital of South Manchester, Manchester, UKAlvar Agustí4Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain5FISIB, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Mallorca, SpainEric D. Bateman6Dept of Medicine, University of Cape Town, Cape Town, South AfricaGonzalo de Miquel2R&D Centre, Almirall, Barcelona, SpainCynthia Caracta7Forest Research Institute, Forest Laboratories Inc., Jersey City, NJ, USAEsther Garcia Gil2R&D Centre, Almirall, Barcelona, Spain
- Inter-relationship of different types of respiratory symptoms in COPDBy Paul W. Jones, Marc Miravitlles, Ferran Chuecos, Esther Garcia Gil and Rosa LamarcaPaul W. Jones1Division of Clinical Science, St George’s, University of London, London, United KingdomMarc Miravitlles2Pneumology Department, Hospital Universitari Vall d’Hebron, Barcelona, SpainFerran Chuecos3R&D Centre, Almirall, Barcelona, SpainEsther Garcia Gil3R&D Centre, Almirall, Barcelona, SpainRosa Lamarca3R&D Centre, Almirall, Barcelona, Spain
- Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classificationBy Robert M. Mróz, Maria Pilar Ausin, Rosa Lamarca and Esther Garcia GilRobert M. Mróz1Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, PolandMaria Pilar Ausin2IMIM. UPF. CIBERE, Hospital del Mar, Barcelona, SpainRosa Lamarca3R&D Centre, Almirall, Barcelona, SpainEsther Garcia Gil3R&D Centre, Almirall, Barcelona, Spain
- Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studiesBy David Price, Mike Thomas, Rosa Lamarca and Esther Garcia GilDavid Price1Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United KingdomMike Thomas2Department of Primary Care Research, University of Southampton, Southampton, United KingdomRosa Lamarca3R&D Centre, Almirall, Barcelona, SpainEsther Garcia Gil3R&D Centre, Almirall, Barcelona, Spain
- Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patientsBy Marc Miravitlles, Esther Garcia Gil, Ferran Chuecos and Rosa LamarcaMarc Miravitlles1Pneumology Department, Hospital Universitari Vall d'Hebron, Barcelona, SpainEsther Garcia Gil2Global Medicines Development, AstraZeneca PLC, Barcelona, SpainFerran Chuecos2Global Medicines Development, AstraZeneca PLC, Barcelona, SpainRosa Lamarca3R&D Centre, Almirall S.A., Barcelona, Spain
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, and a companion volume of self-assessment questions is available. In 2015, the first ERS Practical Handbook, on Noninvasive Ventilation, was added to the series
